Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The British Thoracic Oncology Group (BTOG) 2022 Summer Meeting, held in London on June 8th, featured leading experts in thoracic oncology sharing the latest research developments in screening, early diagnosis, molecular profiling and immunotherapy for thoracic malignancies.

BTOG 2022 Summer Meeting

BTOG 2022 Summer Meeting
08 July 2022 | London, UK

BTOG 2022 Summer Meeting

BTOG 2022 Summer Meeting
08 July 2022 | London, UK
The British Thoracic Oncology Group (BTOG) 2022 Summer Meeting, held in London on June 8th, featured leading experts in thoracic oncology sharing the latest research developments in screening, early diagnosis, molecular profiling and immunotherapy for thoracic malignancies.
Improving immunotherapy outcomes in mesothelioma 1:05
Improving immunotherapy outcomes in mesothelioma
Riyaz Shah • 8 Jul 2022
Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy? 1:27
Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?
Riyaz Shah • 8 Jul 2022
Updates in lung cancer management from the BTOG 2022 Summer Meeting 1:29
Updates in lung cancer management from the BTOG 2022 Summer Meeting
Riyaz Shah • 8 Jul 2022
The centralization of molecular testing 4:04
The centralization of molecular testing
John Gosney • 8 Jul 2022
The BTOG 2022 Summer Meeting 1:09
The BTOG 2022 Summer Meeting
Sanjay Popat • 8 Jul 2022
The British Thoracic Oncology Group (BTOG) 1:20
The British Thoracic Oncology Group (BTOG)
Sanjay Popat • 8 Jul 2022
ctDNA-NGS versus routine tissue testing in patients with advanced NSCLC 2:00
ctDNA-NGS versus routine tissue testing in patients with advanced NSCLC
Sanjay Popat • 8 Jul 2022
A real-world analysis on pembro monotherapy versus pembro + chemotherapy for never-smoking NSCLC 1:25
A real-world analysis on pembro monotherapy versus pembro + chemotherapy for never-smoking NSCLC
Sanjay Popat • 8 Jul 2022
Could ctDNA replace routine tissue testing for genotyping NSCLC? 2:08
Could ctDNA replace routine tissue testing for genotyping NSCLC?
Sanjay Popat • 8 Jul 2022
The use of synthetic control arms to evaluate patients with rare oncogene-driven subsets in NSCLC 1:52
The use of synthetic control arms to evaluate patients with rare oncogene-driven subsets in NSCLC
Sanjay Popat • 8 Jul 2022
Managing epithelial mesothelioma 1:27
Managing epithelial mesothelioma
Riyaz Shah • 8 Jul 2022
The role of immunotherapy for the treatment mesothelioma 1:29
The role of immunotherapy for the treatment mesothelioma
Riyaz Shah • 8 Jul 2022
Challenges faced in the management of brain metastases and large cell neuroendocrine lung cancers 1:07
Challenges faced in the management of brain metastases and large cell neuroendocrine lung cancers
John Conibear • 8 Jul 2022
Lessons learnt from a UK lung SABR rollout program 0:56
Lessons learnt from a UK lung SABR rollout program
John Conibear • 8 Jul 2022
Lessons learnt from a UK lung SABR rollout program 1:51
Lessons learnt from a UK lung SABR rollout program
John Gosney • 8 Jul 2022
Image-guided robotic stereotactic radiosurgery of lung cancer by CyberKnife 0:56
Image-guided robotic stereotactic radiosurgery of lung cancer by CyberKnife
John Conibear • 8 Jul 2022
The content of VJOncology is intended for healthcare professionals